<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175266</url>
  </required_header>
  <id_info>
    <org_study_id>3516</org_study_id>
    <nct_id>NCT00175266</nct_id>
  </id_info>
  <brief_title>Islet Transplantation Using Campath-1H and Infliximab Induction</brief_title>
  <official_title>Islet Transplantation in Type 1 Diabetic Patients Using Campath-1H and Infliximab Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <brief_summary>
    <textblock>
      Islet transplantation has been investigated as a treatment for Type 1 diabetes mellitus in&#xD;
      selected patients with inadequate glucose control despite insulin therapy. However, the&#xD;
      perennial hope that such an approach would result in long-term freedom from the need for&#xD;
      exogenous insulin, with stabilization of the secondary complications of diabetes, has failed&#xD;
      to materialize in practice. The goal of the present study is therefore to improve the safety&#xD;
      and efficacy of clinical islet-alone transplantation by minimizing dependence on&#xD;
      calcineurin-inhibitor therapy - thereby avoiding potential nephrotoxicity, and furthermore&#xD;
      improving success with single-donor islet infusions by avoiding all diabetogenic&#xD;
      immunosuppression. Campath-1H, combined with Infliximab induction therapy provides a unique&#xD;
      opportunity to minimize dosing of maintenance long-term immunosuppression while further&#xD;
      promoting islet engraftment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-centre, prospective, open-label study in Type 1 diabetic participants&#xD;
      receiving an islet cell transplant; all participants will receive Campath-1H + Infliximab&#xD;
      induction therapy followed by sirolimus and ultra-low dose tacrolimus maintenance therapy.&#xD;
&#xD;
      The primary objective of this protocol is to assess the safety of this treatment regimen in&#xD;
      adult Type 1 diabetic participants receiving their first islet transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>islet transplant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must have Type 1 diabetes mellitus for more than 5 years&#xD;
&#xD;
          -  diabetes must be complicated by at least one of the following situations that persist&#xD;
             despite intensive insulin management efforts. The complicating situations are (1)&#xD;
             Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic&#xD;
             symptoms at plasma glucose levels of &lt; 3.0 mmol/L; (2) Metabolic lability/instability,&#xD;
             characterized by MAGE ≥ 11.0 mmol/L and wide swings in blood glucose despite optimal&#xD;
             diabetes therapy; and (3) Despite efforts at optimal glucose control, progressive&#xD;
             secondary complications of diabetes, including retinopathy, neuropathy, or nephropathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe co-existing cardiac disease&#xD;
&#xD;
          -  Active alcohol or substance abuse&#xD;
&#xD;
          -  Psychiatric disorder making the subject not a suitable candidate for transplantation&#xD;
&#xD;
          -  Active infection including hepatitis C, hepatitis B, HIV, or TB&#xD;
&#xD;
          -  Any history of or current malignancies except squamous or basal skin cancer&#xD;
&#xD;
          -  BMI &gt; 28 kg/m2 or body weight &gt; 85 kg at screening visit&#xD;
&#xD;
          -  Positive fasting C-peptide response on assessment (2 positive results)&#xD;
&#xD;
          -  Creatinine clearance &lt; 80 mL/min/1.73 m2&#xD;
&#xD;
          -  Serum creatinine &gt; 150 µmol/L&#xD;
&#xD;
          -  Macroalbuminuria (urinary albumin excretion rate &gt; 300 mg/24h)&#xD;
&#xD;
          -  Baseline Hb &lt; 105g/L in women, or &lt; 130 g/L in men&#xD;
&#xD;
          -  Baseline LFT's outside of normal range&#xD;
&#xD;
          -  Untreated proliferative retinopathy&#xD;
&#xD;
          -  Positive pregnancy test, intent for future pregnancy or male subjects' intent to&#xD;
             procreate, failure to follow effective contraceptive measures, or presently breast&#xD;
             feeding&#xD;
&#xD;
          -  Previous transplant, or evidence of sensitization on PRA&#xD;
&#xD;
          -  Insulin requirement &gt; 1.0 IU/kg/day&#xD;
&#xD;
          -  HbA1C &gt; 0.12&#xD;
&#xD;
          -  Hyperlipidemia (fasting LDL cholesterol &gt; 3.4 mmol/L, treated or untreated; and/or&#xD;
             fasting triglycerides &gt; 2.3 mmol/L)&#xD;
&#xD;
          -  Under treatment for a medical condition requiring chronic use of steroids&#xD;
&#xD;
          -  Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR&#xD;
             &gt; 1.5&#xD;
&#xD;
          -  Untreated Addison's disease&#xD;
&#xD;
          -  Untreated Celiac disease&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.M. James Shapiro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta - Clinical Islet Transplant Program</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>October 1, 2009</last_update_submitted>
  <last_update_submitted_qc>October 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2009</last_update_posted>
  <keyword>islet</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

